MYO
Myomo, Inc.1.0400
+0.0400+4%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
39.97MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
Q2 revenue up 28%, guidance cut
Myomo reported Q2 2025 revenue of $9.7 million, up 28% from last year, driven by 178 MyoPro units sold at a higher average price, though gross margin slipped to 62.7% amid rising costs. Pipeline grew 37% to 1,611 patients, but weaker lead quality from digital ad shifts led to an 18% backlog drop and $4.6 million net loss. The company cut staff by 8% to trim $2 million in spending and updated 2025 revenue guidance to $40-42 million. Lead quality remains a key risk.
10-Q
Q2 FY2025 results
Myomo's Q2 revenue surged 28% year-over-year to $9.7M, driven by higher direct billing units and average sales prices, while six-month totals climbed 73% to $19.5M; gross margins dipped to 62.7% from 70.8% amid rising material and overhead costs. Operating losses widened to $4.6M from $1.1M, fueled by 99% higher R&D and 88% increased selling expenses for clinical expansion and ads, yet net loss per share held at $(0.11) on 41.6M diluted shares. Cash burned $11.5M in operations, offset by $4.0M debt draws, leaving $15.5M in cash and equivalents against $3.8M total debt under a Silicon Valley Bank facility. Revenue relies heavily on Medicare, now 56% of Q2 sales. Prepayment audits by CMS contractors pose reimbursement risks.
CVRX
CVRx, Inc.
8.32+0.14
DHAI
DIH Holding US, Inc.
0.75+0.16
DYNT
Dynatronics Corp.
0.04+0.00
EKSO
Ekso Bionics Holdings, Inc.
4.70+0.05
ELMD
Electromed, Inc.
29.88+0.28
LFWD
Lifeward Ltd.
0.64+0.02
MASI
Masimo Corporation
134.52-2.88
NMTC
NeuroOne Medical Technologies C
0.71+0.05
NPCE
Neuropace, Inc.
15.88-0.04
OSSFF
EMBLA MEDICAL
5.33+0.00